Switzerland· 62903007

Adempas

A riociguat product containing riociguatum, registered in Switzerland and dispensed under Swissmedic category B, on the national reimbursement list. The same ATC class is registered in 17 of our 19 countries.

Reimbursed in Switzerland (BAG SL)Cat B (Swissmedic)ATC C02KX05

Checked against BAG Spezialitätenliste (Switzerland) on

Informational only — not a medical device.

SOURCE REGISTER · CHBAG Spezialitätenliste (Switzerland)normalisedAdempasATCC02KX05REGISTER NO.62903007PACKS LISTED1CHECKEDSeptember 12, 2026

Where it is registered

Riociguat is registered in 17 of 19 countries.

Countries holding a registration under ATC C02KX05 (riociguat), each read from that country’s own register.

  • This record: Switzerland, from BAG Spezialitätenliste (Switzerland)
  • 10 of them publish a price we can compare per daily dose

Riociguat · ATC C02KX05

17 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Icelandprice
  • Ireland
  • Italyprice
  • Japan
  • Netherlands
  • Norwayprice
  • Polandprice
  • Sweden
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of riociguat costs, country by country.

Normalised to the WHO defined daily dose (4.5 mg), the median price runs from $0.056 in France to $219.06 in Switzerland — a ×3926 gap.

  • Switzerland: $219.06 per daily dose (median across products in the class)
  • Public list prices, converted to USD at the rate date shown

Riociguat · price per daily dose (4.5 mg)

USD · FX 28 Sept 2026

  • CH Switzerland$219.06
  • IT Italy$147.94
  • FR France$0.056
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

BAG Spezialitätenliste (Switzerland)
Active substance
riociguatum
Manufacturer
—
Country
Switzerland (CH)
ATC code
C02KX05
ATC class
Riociguat
Defined daily dose
4.5 mg, O
Swissmedic category
B
Reimbursed
Yes
Source register
BAG Spezialitätenliste (Switzerland)
Last checked
September 12, 2026

Packs & prices · 1

1 priced
  • gtin
    7680629030072
    42 Stk
    CHF 1273.75

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

140 interactions on record for riociguat.

Graded by severity as the source publishes them — 10 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Riociguat · interactions on record

140 records

  • 10 severe
  • 103 moderate

Most severe, free to view

  • DipyridamoleB01AC07severe
  • DipyridamolC01DX29severe
  • TheophyllinC01EB28severe
  • KetoconazoleH02CA03severe

27 more interactions with mechanism and management, from a commercially licensed source.

Sign in to check
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Riociguat in 16 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All riociguat products

Authorised across Europe · EMA

The same active substance is authorised in 10 EEA countries. Names it is sold under:

  • Austria · Pahrilan
  • Cyprus · Ridecia
  • Finland · Midive, Riociguat
  • Greece · Ridecia, Riociguat Win Medica
  • Iceland · Adempas
  • Liechtenstein · Adempas
  • Malta · Midive, Riociguat
  • Netherlands · Pahrilan
  • Norway · Adempas
  • Sweden · Pahrilan, Ridecia

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of BAG Spezialitätenliste (Switzerland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/11c0d8be-39b8-4215-afb6-15b2e4e8ab17
GET /v1/drugs/11c0d8be-39b8-4215-afb6-15b2e4e8ab17?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "unit": null,
  "strength": "riociguatum 2 mg",
  "valid_from": "2014-01-01",
  "limitations": "[{\"description\":\"<b>CTEPH:</b> <br>\\nKostengutsprache durch den Krankenversicherer nach vorgängiger Konsultation des Vertrauensarztes im Rahmen der erstmaligen Indikationsstellung durch entsprechend qualifizierte Fachärzte für Pneumologie und Kardiologie zur Behandlung von Patienten mit inoperabler chronisch-thromboembolischer pulmonaler Hypertonie (CTEPH) oder von Patienten mit persistierender oder rezidivierender CTEPH nach operativer Behandlung zur Verbesserung der körperlichen Leistungsfähigkeit.<br>\\n<br>\",\"costApproval\":null,\"indication\":null,\"isNew\":false,\"limitationCode\":null,\"points\":null,\"priceModel\":null,\"title\":null,\"validFrom\":\"2014-01-01\",\"validTo\":null},{\"description\":\"<b>PAH:</b> <br>\\nZur Behandlung erwachsener Patienten mit pulmonaler arterieller Hypertonie (PAH) der WHO-Funktionsklasse II und III zur Verbesserung der körperlichen Leistungsfähigkeit.\",\"costApproval\":null,\"indication\":null,\"isNew\":false,\"limitationCode\":null,\"points\":null,\"priceModel\":null,\"title\":null,\"validFrom\":\"2015-04-01\",\"validTo\":null}]",
  "galenic_form": "Filmtabl 2 mg",
  "therapeutic_area": null,
  "sl_inclusion_date": "2014-01-01",
  "self_retention_pct": 10
}

See everything about riociguat.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.